Systematic review of the YB-1 protein prognostic value in breast cancer patients: overall and progression free survival

Abstract

Breast cancer (BC) is the most common cancer among women worldwide. The role of the multi-Y-box binding protein 1 (YB-1) as a prognostic marker in relation to BC aggressiveness and resistance of tumors to chemotherapy is not sufficiently clear. Objective. The systematic search and analysis of scientific publications describing studies of the predictive power of expression (high, low) and localization (nuclear, cytoplasmic) of YB-1 for overall survival and progression free survival in patients with breast cancer. Methods. A systematic search was carried out in Medline database and the Cochrane Library in April 2014. Of the 88 studies found, we selected for further analysis 2 prospective cohort studies and 7 retrospective studies. We assessed the methodological quality of the selected studies taking into account study design, the risks of systematic biases and risks of incorrect statistical analysis. Results. The included studies varied in their methodological quality (from IIa to IIIc). The expression level (high vs. low) of YB-1 protein when localized in the nucleus of tumor cells is a predictor of overall survival (OS) in patients with breast cancer. The predictive role of cytoplasm localization of YB-1 for OS is not proven. The role of the protein expression level of YB-1 as a predictor ofprogression free survival (PFS) is not proven both for nucleus and cytoplasm localizations. The role of protein localization of YB-1 (nucleus vs. cytoplasm) at high and low levels of expression as a prognostic factor of OS and PFS in patients with breast cancer requires further studies.

Keywords

YB-1 / breast cancer / YB-1 / disease prognosis / overall survival / progression free survival / systematic review

References

[1] Рак молочной железы: профилактика и борьба. 13 мая 2014 года. Available at: http://www.who.int/cancer/detection/breastcancer/ru/.

[2] Елисеева И.А., Ким Е.Р., Гурьянов С.Г., Овчинников Л.П., Лябин Д.Н. Y-бокс связывающий белок (YB-1) и его функции. Успехи биологической химии. 2011; 51: 65-132.

[3] Генс Г.П., Стромская Т.П., Калита О.В., Вайман А.В., Рыбалкина Е.Ю., Овчинников Л.П. и др. Исследование белка YB-1 в опухолях молочной железы. Клиническая лабораторная диагностика. 2009; 4: 21-4.

[4] Mylona E., Melissaris S., Giannopoulou I., Theohari I., Papadimitriou C., Keramopoulos A. et al. Y-box-binding protein 1 (YB1) in breast carcinomas: Relation to aggressive tumor phenotype and identification of patients at high risk for relapse. Eur. J. Surg. Oncol. 2014; 40 (3): 289-96.

[5] Maciejczyk A., Szelachowska J., Ekiert M., Matkowski R., Halon A. , Lage H. et al. Elevated nuclear YB1 expression is associated with poor survival of patients with early breast cancer. Anticancer Res. 2012; 32 (8): 3177-84.

[6] Lasham A., Samuel W., Cao H., Patel R., Mehta R., Stern J.L. et al. YB-1, the E2F pathway, and regulation of tumor cell growth. J. Natl. Cancer Inst. 2012; 104 (2): 133-46.

[7] Xie W., Yang J., Cao Y., Peng C., Ning H., Zhang F. et al. Expression of Y-Box-binding protein 1 in Chinese patients with breast cancer. Tumor Biol. 2012; 33 (1): 63-71.

[8] Gluz O., Mengele K., Schmitt M., Kates R., Diallo-Danebrock R., Neff F. et al. Y-Box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J. Clin. Oncol. 2009; 27 (36): 6144-51.

[9] Dahl E., En-Nia A., Wiesmann F., Krings R., Djudjaj S., Breuer E. et al. Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer. BMC Cancer. 2009; 9 (1): 410.

[10] Habibi G., Leung S., Law J.H., Gelmon K., Masoudi H., Turbin D. et al. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res. 2008; 10 (5): 86.

[11] Fujii T., Kawahara A., Basaki Y., Hattori S., Nakashima K., Nakano K. et al. Expression of HER2 and estrogen receptor a depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res. 2008; 68 (5): 1504-12.

[12] Janz M., Harbeck N., Dettmar P., Berger U., Schmidt A., Jurchott K. et al. Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int. J. Cancer. 2002; 97 (3): 278-82.

RIGHTS & PERMISSIONS

Eco-Vector